Hepatic veno-occlusive disease is a serious regimenrelated toxicity in patients undergoing hematopoietic stem cell transplantation. We performed a systematic review and meta-analysis of the literature on the effect of anticoagulation in preventing veno-occlusive disease. Several databases and online journals were searched for randomized controlled trials and cohort studies. Twelve studies (2782 patients) were eligible. Anticoagulation prophylaxis was associated with a statistically nonsignificant decrease in risk of veno-occlusive disease (pooled relative risk (RR), 0.90; 95% confidence interval (CI), 0.62-1.29). Results of one of three randomized controlled trials may have been affected by delayed introduction of anticoagulation. A second trial enrolled patients who received conventional chemoradiotherapy for early-stage disease (RR, 0.18; 95% CI, 0.04-0.78). The third trial was a pilot study with a small sample size (RR, 0.74; 95% CI, 0.53-1.04). Significant heterogeneity and methodologic weaknesses preclude drawing a meaningful conclusion from the pooled analysis. Despite some limitations, results of two of three eligible randomized controlled trials suggest that prophylactic anticoagulation may help prevent veno-occlusive disease. However, a large randomized controlled trial is needed for confirmation. Additionally, in future studies, owing to the wide spectrum of severity of veno-occlusive disease, outcomes such as 100-day mortality should strongly be considered.
Introduction
Tremendous progress has been made in the field of hematopoietic stem cell transplantation during the past three decades. As new indications emerge and donor pools expand with advanced histocompatibility knowledge and improved supportive care, the number of hematopoietic stem cell transplantations continues to increase. However, this improvement is accompanied by an increase in regimen-related toxicities due to chemoradiotherapy used as conditioning regimens. Toxicities include severe infections, organ damage, graft-versus-host disease and hepatic veno-occlusive disease.
Veno-occlusive disease is considered a leading cause of hematopoietic stem cell transplantation-related deaths, with a reported mortality rate of up to 50%. [1] [2] [3] [4] To date, no medical therapy has proven effective for the treatment of veno-occlusive disease. [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] Even with a recent shift to a low-intensity conditioning regimen (e.g., fludarabinecontaining regimens), veno-occlusive disease continues to be a concern. [16] [17] [18] [19] Preventive strategies to decrease hepatic sinusoidal injury and subsequent thrombosis have not been convincing. [20] [21] [22] Prophylactic anticoagulation with lowdose unfractionated heparin (UFH) or low-molecularweight heparin (LMWH) has been of particular interest and has garnered much attention for more than a decade. Despite this attention, the topic remains controversial. [23] [24] [25] [26] Therefore, we performed a systematic review and metaanalysis of the literature to investigate the effect of anticoagulation in preventing veno-occlusive disease in pediatric and adult patients undergoing hematopoietic stem cell transplantation following the Meta-analysis of Observational Studies in Epidemiology (MOOSE) 27 and Quality of Reporting of Meta-analyses (QUOROM) 28 guidelines.
Methods

Identification of the relevant literature
We performed a comprehensive search of several databases (from inception to Box 1 shows the MEDLINE search string. The search strategy included using subject headings related to intervention (heparin, LMWH) or the general term 'heparin'; a combination of subject headings related to outcome (hepatic veno-occlusive disease, hepatic venous thrombosis) or the key word 'sinusoidal obstruction syndrome'; and the subject headings 'stem cell transplantation' and 'anticoagulants. ' The search strategy for other databases was generally the same, with the use of either key words or terms specific to a particular database.
Expertise of a librarian was sought for the search. Two reviewers (AZ and HI) examined titles and abstracts. Abstracts were regarded relevant if they described use of prophylactic heparin in the study. Bibliographies and review articles were reviewed manually for additional citations, and both reviewers examined full manuscripts of all relevant articles. Authors were contacted for unpublished data and clarification of reported data and methodologies. Our search was not limited to Englishlanguage publications. Agreement between observers for study eligibility and study validity was examined using the k statistic. Disagreements were resolved by consensus. Two investigators (HI and AZ) independently identified eligible studies and assessed their quality. One investigator (HI) abstracted the data. The proportion of studies identified initially that met the selection criteria was 0.11.
Criteria for inclusion and exclusion of studies in the review
To be included, a study had to meet the following criteria: (1) be a randomized controlled trial or an observational cohort study, (2) compare the use of either UFH or LMWH for anticoagulation with a nontherapeutic control, (3) study patients who were children or adults undergoing myeloablative therapy followed by hematopoietic stem cell transplantation and (4) report on the incidence of hepatic veno-occlusive disease. Because of the paucity of the relevant literature, we did not specify any exclusion criteria.
Outcome definitions
Diagnosis of veno-occlusive disease was defined by use of histologic criteria on liver biopsy findings or one of the following sets of criteria: Seattle, modified Seattle or Baltimore (Table 1) .
Data collection
A structured data extraction form was developed, and relevant information was abstracted from each study. Pertinent data included study characteristics (year and country), patient characteristics (demographic variables, donor type, underlying disease, preparative regimens, interventions and adverse events) and outcome definitions. We extracted the total number of patients and venoocclusive disease events in intervention and control groups both for clinical trials and for cohort studies. If they were reported, we also recorded available outcome data separately for autologous and allogeneic transplant recipients and the adjusted risk ratios and 95% confidence intervals (CIs) based on the multivariable regression model.
Two reviewers (HI and AZ) independently assessed the methodologic quality of included studies using the validity criteria proposed by Juni et al. 30 for randomized clinical trials and the Newcastle-Ottawa Scale for cohorts studies. 31 Disagreements were resolved by consensus.
Data analysis
The meta-analytic comparison was based on relative risk (RR) estimates from each study. Expecting heterogeneity, 33 Stratified analyses were performed and a statistical test of interaction was used to evaluate the extent to which subgroup results differed from each other. 34 Subgroups were specified a priori according to the study population (allogeneic vs autologous transplant recipients), study design (randomized clinical trials vs cohort studies), intervention (UFH vs LMWH) and outcome definition (Seattle or modified Seattle criteria vs Baltimore criteria; Seattle vs modified Seattle or Baltimore criteria). All analyses were performed with RevMan software Version 4.2.7 (The Cochrane Collaboration, Oxford, UK). The level of significance was set at P less than 0.05. Figure 1 is a flow diagram of the studies identified for this review. The search resulted in identifying 17 studies, 5, [23] [24] [25] [26] [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] 12 of which were found to be eligible. 24, 26, [35] [36] [37] [38] [39] [40] [41] [42] [43] [44] Three studies were published as abstracts. 35, 36, 42 The observed agreement on study eligibility was 94%, and thus, 6% of the time a consensus had to be reached by discussion; then, both investigators accepted a joint decision.
Results
Studies meeting the inclusion criteria for analysis
The k statistic for interobserver agreement on eligibility of the studies was 0.85. Conceptually, k (a statistic used to measure nonrandom agreement between observers, investigators or measurements) accounts for the observed agreement by chance and informs the clinician of the extent of possible agreement over and above chance. A value of k from 0.81 to 0.99 means almost perfect agreement, and a value from 0.61 to 0.80 means substantial agreement. Table 2 describes the characteristics of the studies that met the inclusion criteria. The studies included a total of 2782 hematopoietic stem cell transplantation patients who had various hematologic and solid malignancies, benign hematologic disorders, bone marrow failure syndromes and nonmalignant diseases. Sample sizes ranged from less than 50 to more than 1000 patients. Conditioning therapy varied among studies and included high-intensity and lowintensity regimens. The overall veno-occlusive disease incidence rate in the control group ranged from 2 to 82%. Two studies were restricted to autologous transplant recipients, 39, 40 two to allogeneic transplant recipients, 36, 41 and the rest included both donor types. Most of the studies included both children and adults.
Study characteristics
In the eligible studies, either LMWH 26, 36, 37, 43 or UFH 24, 35, [37] [38] [39] [40] [41] [42] [43] [44] was used as the intervention. Two studies reported both LMWH and UFH groups. 37, 43 Most of the studies used a dosage of 100 U/kg per day as a continuous infusion for UFH. 24, 35, 37, 38, 40, 42, 44 The dose of LMWH (enoxaparin) was 60 mg/day subcutaneously in two studies 36, 37 and 40 mg/day subcutaneously in another. 26 Duration of anticoagulation did not differ substantially among studies, ranging from the day of conditioning to day þ 40 after hematopoietic stem cell transplantation or discharge; however, anticoagulation was started on the day of marrow infusion in one study. 39 Time of initiation or duration of anticoagulation was not reported in a few studies. 36, 41, 43, 44 Outcome was defined according to the Seattle criteria in most of the studies. Liver biopsy was performed for uncertain cases in two studies. 24, 43 Outcome data (incidence of veno-occlusive disease) were available for all the studies except one, which were subsequently provided by the author. 26 One study reported the results of an unpublished randomized controlled trial in conjunction with a cohort study; however, the outcome was reported separately. 39 Adverse events (bleeding) were reported or discussed in seven of the 12 studies. 24, 26, [36] [37] [38] [39] 42 Overall severity of venoocclusive disease was reported in nine studies. 24, [36] [37] [38] [39] [40] [42] [43] [44] In three studies, 37, 38, 42 the anticoagulation group had a lower incidence of severe cases, and in one study, 24 none of the patients had severe disease. Tables 3 and 4 summarize the different domains of study quality. Randomized clinical trials were judged according to the key validity components that address biases in selection, performance, detection and sample attrition. Only one trial met all the criteria for validity. The observed agreement was 100%, and the k statistic for interobserver agreement on these quality domains was 1 (perfect agreement). Observational cohort studies were assessed according to the Newcastle-Ottawa Scale for quality assessment, which is intended to assess for selection bias, comparability of the exposed and unexposed cohorts, outcome assessment and attrition bias. Studies included in this meta-analysis were representative of patients undergoing myeloablative therapy followed by hematopoietic stem cell transplantation. All studies had adequate followup and outcome assessment methods. Hence, quality assessment was based on the two domains (selection of the controls and comparability of the groups). The observed agreement on these two key domains of validity for the observational studies was 60 and 80%, thus requiring consensus 40 and 20% of the time, respectively. All disagreements were resolved by consensus reached by discussion; then, both investigators accepted a joint decision. The k statistic for interobserver agreement on these two key domains was 0.6 and 0.7.
Quality assessment
Quantitative results of the meta-analysis Figure 2 displays the cumulative meta-analytic comparison. The overall RR was 0.90 (95% CI, 0.62-1.29) using the random effects model, for veno-occlusive disease developing in patients undergoing hematopoietic stem cell transplantation and receiving anticoagulation prophylaxis. There was evidence of significant heterogeneity between the studies (Po0.0001, w 2 test), and the I 2 was 68.2%.
Results of the stratified analysis
We explored reasons for between-study heterogeneity by performing a priori hypothesized subgroup analyses. We expected that the RRs might vary depending on (1) study population (allogeneic vs autologous transplant recipients), (2) study design (randomized clinical trials vs cohort studies), (3) intervention (UFH vs LMWH), (4) outcome definitions based on the Seattle or modified Seattle criteria vs the Baltimore criteria and (5) outcome definitions based on the Seattle criteria vs the modified Seattle or Baltimore criteria. Table 5 summarizes the different subgroup analyses. None of the RR estimates was statistically significant. However, all five subgroups were significantly different (for the test of interaction, Po0.0001, P ¼ 0.04, P ¼ 0.004, P ¼ 0.008 and P ¼ 0.01, respectively). Heterogeneity based on different dosages and duration of the intervention was not explored because it is unlikely that the slightly different dosages and minor individual variations in the duration of UFH and LMWH between the studies had different clinical effects. Differences in age and sex distribution of the study populations as well as underlying disease (nonmalignant or malignant; early or advanced) can contribute to the observed variation in treatment effect. Unfortunately, we were not able to analyze these factors because these data were not available.
Discussion
This systematic review highlights the inconsistencies among studies addressing the role of anticoagulation in the prevention of veno-occlusive disease. Our review identified 12 studies that addressed the relationship between anticoagulation and hepatic veno-occlusive disease. The metaanalytic comparison revealed a statistically nonsignificant beneficial effect of anticoagulation. However, the extreme diversity of the studies precludes making meaningful conclusions from the pooled analysis. This review included 10 cohort studies, four of which were well designed to identify risk factors for Moreover, all 10 studies had methodologic limitations. Unlike randomized clinical trials, treatment allocation is not concealed in a cohort study of efficacy. Thus, they are vulnerable to confounding by indication. Indeed, in some studies, anticoagulation was administered only to high-risk patients, who theoretically could mask its beneficial effect. 35, 39, 43 However, the control groups, some of which were relatively recent, were historical in the majority of studies. With the dynamic advances in the field of stem cell transplantation and improvement in supportive medical Table 3 Quality assessment of the randomized controlled trials according to the components proposed by Juni et al.
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Type of bias Item Source
Attal et al. 24 Or et al. 26 Marsa-Vila et al. e Comparability of cohorts on the basis of the design or analysis: A, study controls for the most important factor (conditioning regimen); B, study controls for any additional factor (donor type, previously increased levels of liver enzymes, graft-versus-host disease prophylaxis, etc.); C, not carried out or not reported. f A, independent blind assessment; B, record linkage; C, self-report; D, no description. g Was follow-up long enough for outcomes to occur? A, yes; B, no. h A, complete follow-up; all subjects were accounted for. B, Subjects lost to follow-up were unlikely to introduce bias because small numbers were lost; 490% had follow-up, or description was provided of those lost. C, follow-up rate o90%, and there was no description of those lost. D, no statement.
care, such comparisons are inevitably also prone to selection bias. Several risk factors have been reported in the literature. [1] [2] [3] 43, [47] [48] [49] Bias in comparability may exist if the risk profile is not the same for both intervention and control groups. For example, differences in transplant type, conditioning regimen including total body irradiation dosing, preexisting liver dysfunction, variations in cyclophosphamide metabolism or other patient-related risk factors between the two groups could lead to systematic error. Controlling for important risk factors in a statistical model can deal with known confounders. However, an adjusted RR was reported by only one study. 37 Hence, the evidence from the cohort studies has a limitation of being biased in either comparability or selection of the cohorts.
Three randomized controlled trials were eligible for this review. In one of the trials, anticoagulation was started on the day of marrow infusion rather than at conditioning. 39 The results of this study may have been affected by the delayed introduction of anticoagulation. Two other trials in which anticoagulation was started at conditioning showed a decreased risk of veno-occlusive disease. The RR for the study by Attal et al. 24 was 0.18 (95% CI, 0.04-0.78). This open-label study of low-dose UFH comprised patients who received conventional chemoradiotherapy, which, for most, was given at an early stage of the disease. Thus, the results of this trial may not be generalizable to all patients undergoing hematopoietic stem cell transplantation. The third trial, a pilot study by Or et al., 26 had an RR of 0.74 (95% CI, 0.53-1.04). The results were not statistically significant, primarily owing to lack of power. The study was designed to address the safety and not the efficacy of LMWH. It was a double-blind, placebo-controlled trial that met all the validity criteria. However, the small sample size may have affected adequate randomization. Furthermore, patient-important outcomes, such as mortality or severity, are preferable measures of treatment efficacy. However, none of these trials were powered to detect a difference in severe veno-occlusive disease. These limitations, despite the overall favorable results of these trials, add to the conundrum and limit the extent to which positive conclusions can be drawn on the beneficial effect of anticoagulation.
In the presence of considerable heterogeneity, a pooled estimate is not appropriate and may not reflect the true Figure 2 Meta-analysis of studies comparing patients receiving prophylactic anticoagulation with controls for prevention of veno-occlusive disease (VOD)
in patients undergoing hematopoietic stem cell transplantation. CI, confidence interval; LMWH, low-molecular-weight heparin; N, number of patients at risk of developing VOD; n, number of patients who developed VOD; RR, relative risk; UFH, unfractionated heparin. 36, 41 . Among studies that included both types of transplant recipients, two studies 24, 42 provided separate outcome data for autologous and allogeneic transplant recipients. Hepatic veno-occlusive disease H Imran et al underlying effect. Nevertheless, we combined the data to explore heterogeneity. Much of the heterogeneity was explained through subgroup analyses. The effect of anticoagulation differed with respect to the donor type of recipients (allogeneic vs autologous), study design (randomized controlled trial vs cohort), type of anticoagulation (LMWH vs UFH) and outcome definition used (Seattle or modified Seattle criteria vs Baltimore criteria; Seattle criteria vs modified Seattle or Baltimore criteria). Although the results should be interpreted with caution, they generate hypotheses that merit further attention in future studies.
It is possible that some heterogeneity may have remained unexplained. Differences in age and sex distribution of the study populations as well as underlying disease (nonmalignant or malignant; early or advanced) can contribute to the observed variation in treatment effect. Unfortunately, we were not able to analyze these factors because these data were not available. Quality of the included studies is another factor that may account for the heterogeneity because all cohort studies had methodologic problems.
Adverse events are another important aspect of anticoagulation therapy. The risk of major bleeding was low at the UFH and LMWH dosages used in these studies. Seven out of 12 studies reported bleeding as an adverse event: in two studies patients had major bleeding episodes, and in five studies patients had only minor hemorrhages. Table 2 summarizes these adverse events in detail. In none of the studies were these events found to be more frequent in the anticoagulation group than in the control group. However, in a pilot study of low-dose prophylactic anticoagulation for prevention of veno-occlusive disease, 50% of the participants had to be withdrawn because of either increased bleeding or anticipated bleeding. 5 Thus, use of anticoagulation merits careful consideration before it is undertaken. Heparin-induced thrombocytopenia is also a known complication of anticoagulation. However, its clinical diagnosis is difficult in transplant patients. One study in our review reported heparin-induced thrombocytopenia as a rare possibility in its patients. 39 Our analysis has possible limitations. Disease misclassification is a potential concern because it is challenging to distinguish veno-occlusive disease from other possible causes of liver dysfunction, especially acute graft-versushost disease and sepsis. With the potential risk of bleeding, liver biopsy, which provides histologic confirmation, is rarely performed. Usually the diagnosis is made on the basis of the clinical criteria proposed by McDonald et al. 2 and Jones et al. 4 One study reported that the specificity of the Seattle criteria varies if only two of the three clinical data are met. 50 Because most of the studies used the Seattle criteria, diagnosis misclassification was possible. Additionally, late veno-occlusive disease cases occurring after the time specified by these criteria may have been unrecognized.
Publication bias is another possible limitation. We did not perform a manual search, and only one author was able to provide unpublished data; 42 thus, we may not have identified all relevant literature on this topic. Nevertheless, our process of literature identification was comprehensive and was performed with the help of an experienced librarian, so that it should have identified the majority of published studies that examined the association between prophylactic anticoagulation and prevention of venoocclusive disease. The small number of studies, however, limits our ability to assess for publication bias (for instance, using a funnel plot) or to draw conclusions about publication bias. The patient population examined in this systematic review involved both children and adults with various underlying hematologic and nonhematologic malignancies as well as benign hematologic disorders. Therefore, the conclusions can be generalized to all patients undergoing hematopoietic stem cell transplantation who receive myeloablative chemotherapy.
Conclusion
Heterogeneity and methodologic weaknesses of the cohort studies preclude drawing a meaningful conclusion from the pooled analysis. The results of two randomized controlled trials in which anticoagulation was started at the time of conditioning suggest the possibility of a beneficial effect of prophylactic anticoagulation in decreasing the risk of venoocclusive disease; however, they have limitations as well. Furthermore, no study was powered to detect a difference in the rate of severe veno-occlusive disease. Therefore, an adequately powered randomized controlled trial of only high-risk patients is needed, with particular emphasis on stratification based on known risk factors and donor type. In future studies, owing to the wide spectrum of severity of veno-occlusive disease, outcomes such as 100-day mortality should strongly be considered.
